RESTORING LIFE TO CANCER CACHEXIA PATIENTS
MetaboCure is dedicated to developing innovative biopharmaceutical solutions for cancer cachexia and other metabolic disorders
THE PROBLEM
Cancer cachexia (wasting syndrome) kills over 2.9 million people annually around the world!
The global numbers for the last analysis that was done at the end of 2022 are:
Global cancer patients:
53,503,187
New annual cancer cases:
19,976,499
Annual cancer deaths:
9,743,852
30% of all cancer patients get cachexia
Cachexia is a complex, debilitating syndrome seen in advanced cancer patients, characterized by severe weight loss, muscle wasting, and reduced appetite. It results from metabolic changes driven by the tumor and the body's inflammatory response, leading to decreased quality of life and limited treatment tolerance. Cachexia is challenging to reverse and often signals poor prognosis in cancer patients.
There is no cure for cachexia.
Responsible for 30% of all cancer deaths; around 2.9M annually
Cachexia is responsible for 85% of all gastric cancer deaths and 83% of all pancreatic cancer deaths, meaning that if we cure Cachexia, we give the vast majority of the aggressive cancers patients a true chance to fight.
METABOCURE SOLUTION
MetaboCure and our Nuforal drug.
We have deciphered the biochemical and molecular mechanisms underlying cachexia, discovering that the transcription factor HNF4α, crucial for regulating liver metabolism, is suppressed during the disease, leading to macromolecule breakdown, which the tumor exploits to fuel its growth.
By restoring HNF4α levels in the liver of cancer mouse models, using HNF4α mRNA, the symptoms are reversed as is evident by reduced weight loss, tumor shrinkage, and improved survival rates.
MetaboCure is developing Nuforal, an HNF4α mRNA/LNP-based drug, for the treatment of cancer cachexia.
Nuforal showed a very encouraging results in animal models:
The weight loss and muscle wasting stopped and returned to normal
The cancer tumor stopped growing